FOR 5298: iMAGO - Personalized diagnostics for the treatment of obesity

肥胖症是一种非传染性的广泛流行的疾病。它增加了患2型糖尿病、高血压、脂肪代谢紊乱和其他合并症的风险。肥胖症在人群中的高患病率由于患者中普遍存在的大规模健康限制和死亡率增加而导致显著的医疗保健成本。然而，长期有效的治疗可持续减肥和积极影响的新陈代谢仍然是不可用的。通过限定的生活方式干预（如热量限制和/或运动训练）短期成功减肥显示出相当大的个体差异。在生活方式干预的过程中，识别这些代谢类型的生物标志物及其代谢适应性以保护身体脂肪储存，将有助于在早期发现这些适应性的发生，并适当地调整每个人的干预类型和强度。研究组旨在进一步开发和应用新的非-基于光声和磁共振的侵入性成像技术，用于安全和纵向监测能量和脂质代谢参数，特别是体内脂肪组织和肌肉中的参数。这包括动态测量血红蛋白（氧合/脱氧）、氧饱和度、血容量和流速、脂质分布以及细胞和组织中的脂质和水含量。在对肥胖、胰岛素抵抗和糖尿病参与者的试点研究中，我们将记录和分析这些参数在急性代谢挑战（测试餐、暴露于寒冷、训练）期间的动态反应，以确定个体代谢型的生物标志物。我们将使用和评估新的成像技术，在热量限制或运动训练的干预研究中检测和纵向监测选定的生物标志物。特别是，我们感兴趣的生物标志物，反映在干预过程中肌肉和脂肪组织的代谢适应，并与全身代谢状态的积极变化。我们的研究单位将调查这些生物标志物对个性化生活方式干预的适用性。长期目标是通过对当前代谢状态的无标记测量开发新的诊断方法，这将为治疗超重和肥胖症的个性化营养和药物创造新的可能性。

Obesity is one of the non-communicable widespread diseases. It increases the risk of developing type 2 diabetes, high blood pressure, lipometabolic disorders, and other comorbidities. The high prevalence of obesity in the population causes significant health care costs due to widespread massive health restrictions in patients and increased mortality. However, long-term effective therapy for sustainable weight reduction and positive influence on the metabolism is still not available. Short-term successful weight loss through defined lifestyle interventions, such as caloric restriction and/or exercise training, shows considerable individual variation. The identification of biomarkers for these metabotypes and their metabolic adaptations to defend body fat stores in the course of lifestyle interventions would help to detect the onset of these adaptations at an early stage and appropriately adjust the type and intensity of the interventions for each individual.The Research Unit aims to further develop and apply new non-invasive imaging technologies based on optoacoustics and magnetic resonance for safe and longitudinal monitoring of parameters of energy and lipid metabolism, in particular in adipose tissue and muscle in vivo. This includes dynamic measurements of hemoglobin (oxygenated/deoxygenated), oxygen saturation rate, blood volume and flow rate, lipid profiles, as well as lipid and water content in cells and tissues. In pilot studies with participants with obesity, insulin-resistance and diabetes we will record and analyze the dynamic responses of these parameters during acute metabolic challenges (test meal, exposure to cold, training) in order to identify biomarkers for individual metabotypes. We will use and evaluate the new imaging technologies for detection and longitudinal monitoring of selected biomarkers in an intervention study with caloric restriction or exercise training. In particular, we are interested in biomarkers that reflect metabolic adaptations in muscle and fat tissue during the course of the intervention and are associated with positive changes in the systemic metabolic status. Our Research Unit will investigate the suitability of such biomarkers for personalizing lifestyle interventions. The long-term goal is the development of new diagnostic approaches through label-free measurement of the current metabolic status, which will create new possibilities in personalized nutrition and medicine for the treatment of overweight and obesity.